JP2023500819A5 - - Google Patents

Info

Publication number
JP2023500819A5
JP2023500819A5 JP2022524045A JP2022524045A JP2023500819A5 JP 2023500819 A5 JP2023500819 A5 JP 2023500819A5 JP 2022524045 A JP2022524045 A JP 2022524045A JP 2022524045 A JP2022524045 A JP 2022524045A JP 2023500819 A5 JP2023500819 A5 JP 2023500819A5
Authority
JP
Japan
Prior art keywords
cancer
markers
determining
nid1
ptx3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022524045A
Other languages
English (en)
Japanese (ja)
Other versions
JP7797382B2 (ja
JP2023500819A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2020/051155 external-priority patent/WO2021077181A1/en
Publication of JP2023500819A publication Critical patent/JP2023500819A/ja
Publication of JP2023500819A5 publication Critical patent/JP2023500819A5/ja
Application granted granted Critical
Publication of JP7797382B2 publication Critical patent/JP7797382B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022524045A 2019-10-24 2020-10-26 がん診断 Active JP7797382B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904005 2019-10-24
AU2019904005A AU2019904005A0 (en) 2019-10-24 A cancer diagnostic
PCT/AU2020/051155 WO2021077181A1 (en) 2019-10-24 2020-10-26 A cancer diagnostic

Publications (3)

Publication Number Publication Date
JP2023500819A JP2023500819A (ja) 2023-01-11
JP2023500819A5 true JP2023500819A5 (https=) 2023-11-06
JP7797382B2 JP7797382B2 (ja) 2026-01-13

Family

ID=75619520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524045A Active JP7797382B2 (ja) 2019-10-24 2020-10-26 がん診断

Country Status (8)

Country Link
US (1) US20220365089A1 (https=)
EP (1) EP4049027A4 (https=)
JP (1) JP7797382B2 (https=)
KR (1) KR20220092902A (https=)
CN (1) CN115380215B (https=)
AU (1) AU2020370867A1 (https=)
CA (1) CA3158472A1 (https=)
WO (1) WO2021077181A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116466085A (zh) * 2022-11-28 2023-07-21 中国人民解放军海军军医大学第三附属医院 一种四基因的生物标志物组合及其在肝癌治疗中的应用
WO2025050605A1 (en) * 2023-09-05 2025-03-13 The University Of Hong Kong Nidogen 1 as a diagnostic marker and therapeutic target of hepatocellular carcinoma, composition and methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
CA2886607A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
JP2018136122A (ja) * 2015-05-29 2018-08-30 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
CN106188244B (zh) * 2015-05-29 2019-12-27 王育民 抑制癌细胞活性的短肽治疗剂及含有它的医药组合物
EP3543701A4 (en) * 2016-10-28 2020-07-29 Japanese Foundation For Cancer Research BIOMARKER, METHOD OF SEARCHING FOR A GENE ASSOCIATED WITH A DISEASE, AND MARKER FOR KIDNEY CANCER
WO2018094469A1 (en) * 2016-11-24 2018-05-31 The Council Of The Queensland Institute Of Medical Research Determining a cancer prognosis
EP3716986A4 (en) * 2017-12-01 2022-02-09 Cornell University NANOPARTICLES AND VARIOUS EXOSOME SUBSETS FOR CANCER DETECTION AND TREATMENT
US12123058B2 (en) * 2018-01-25 2024-10-22 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer

Similar Documents

Publication Publication Date Title
Chen et al. Prognostic fifteen-gene signature for early stage pancreatic ductal adenocarcinoma
Zhu et al. High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma
Li et al. Identification and prognostic analysis of biomarkers to predict the progression of pancreatic cancer patients
ES2700367T3 (es) Nuevos biomarcadores para el cáncer de mama metastásico
Köhler et al. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients
JP2012500389A5 (https=)
ES2772701T3 (es) Uso de nucleosomas libres de células como biomarcadores en muestras de esputo
JP2014062914A (ja) 肝細胞癌と関連するシグネチャ遺伝子を利用する検査方法、及び該方法に用いられるアレイ又はキット
JP2012526544A5 (https=)
WO2010000907A1 (es) Huella genómica de cáncer de mama
CN106662543A (zh) 肺癌患者中的非侵入性基因突变检测
JP2020507760A (ja) 方法、アレイ、およびそれらの使用
Tao et al. Predicting the response of neoadjuvant therapy for patients with esophageal carcinoma: an in-depth literature review
JP2023500819A5 (https=)
WO2014198995A1 (es) Biomarcadores para el diagnóstico y respuesta al tratamiento en cáncer de páncreas
BR112020020877A2 (pt) selecionar pacientes para terapia com inibidores de sinalização de adenosina
CN102472753A (zh) 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法
US20160003848A1 (en) Method for predicting therapy efficacy using nucleosome structure biomarkers
Allingham-Hawkins et al. ERCC1 expression analysis to guide therapy in non-small cell lung cancer
ES2775178T3 (es) Uso de nucleosomas libres de células como biomarcadores en muestras fecales
ES3015694T3 (en) Method for the prediction or prognosis of the response of a human subject suffering from cancer to treatment with an antagonist of the nk1 receptor
ES2897677T3 (es) Olfactomedina-4, neudesina y desmoplaquina como nuevos biomarcadores del cáncer de mama
Kim et al. Combined Application of CEA, CA 15-3, and CA 27-29 for the Evaluation of Diagnostic Performance in Canine Mammary Gland Tumors
Cherciu et al. Targeted Confocal Laser Endomicroscopy (CLE) for the Assessment of Putative Cancer Stem Cell Markers in Colorectal cancer-A Pilot Study
Gomceli et al. Preoperative serum levels of soluble endoglin for prediction of recurrence in stage III colorectal cancer patients